{ "id": "eprgs9w6y4", "slug": "bendamustine-and-rituximab-regimen", "title": "Bendamustine and rituximab regimen", "updated": "2026-10-15", "topic_path": [ { "id": "life", "label": "Life and health", "api_url": "https://www.edgepedia.org/api/v1/topics/life" }, { "id": "life.health", "label": "Human health and medicine", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health" }, { "id": "life.health.medicines", "label": "Medicines and therapeutics", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.medicines" }, { "id": "life.health.medicines.cancer-chemotherapy", "label": "Cancer chemotherapy and regimens", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.medicines.cancer-chemotherapy" }, { "id": "life.health.medicines.cancer-chemotherapy.immunotherapy-and-immunochemotherapy", "label": "Immunotherapy and immunochemotherapy", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.medicines.cancer-chemotherapy.immunotherapy-and-immunochemotherapy" } ], "geo": [ { "id": "geo.eeu.t1946.life.health", "label": "Eastern Europe · 1946 to 2000: Human health and medicine", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.eeu.t1946.life.health", "path": [ { "id": "geo.eeu", "label": "Eastern Europe", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.eeu" }, { "id": "geo.eeu.t1946", "label": "Eastern Europe · 1946 to 2000", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.eeu.t1946" }, { "id": "geo.eeu.t1946.life", "label": "Life and health", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.eeu.t1946.life" }, { "id": "geo.eeu.t1946.life.health", "label": "Human health and medicine", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.eeu.t1946.life.health" } ] }, { "id": "geo.eeu.t2001", "label": "Eastern Europe · 2001 to 2020", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.eeu.t2001", "path": [ { "id": "geo.eeu", "label": "Eastern Europe", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.eeu" }, { "id": "geo.eeu.t2001", "label": "Eastern Europe · 2001 to 2020", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.eeu.t2001" } ] } ], "excerpt": "The bendamustine and rituximab (BR) regimen is a chemoimmunotherapy combination pairing the alkylating drug bendamustine with the antibody rituximab, given in up to six 28-day cycles for B-cell malignancies including indolent lymphoma and CLL.", "snippet": "The bendamustine and rituximab (BR) regimen is a chemoimmunotherapy combination pairing the alkylating drug bendamustine with the antibody rituximab, given in up to six 28-day cycles for B-cell malignancies including indolent lymphoma and CLL.", "node": "life.health.medicines.cancer-chemotherapy.immunotherapy-and-immunochemotherapy", "markdown": "# Bendamustine and rituximab regimen\n\nThe bendamustine and rituximab (BR) regimen is a chemoimmunotherapy combination that pairs the alkylating drug bendamustine with the anti-CD20 antibody rituximab to treat B-cell malignancies, including indolent non-[Hodgkin lymphoma](https://www.edgepedia.org/hodgkin-lymphoma) (NHL), mantle cell lymphoma, and chronic lymphocytic leukemia (CLL). In its standard form it consists of bendamustine 90 mg/m2 intravenously on days 1 and 2 with rituximab, repeated every 28 days for up to six cycles.[1](https://www.bccancer.bc.ca/chemotherapy-protocols-site/Documents/Lymphoma-Myeloma/LYBENDR_Protocol.pdf) Trials established BR over R-CHOP in first-line indolent and mantle cell lymphoma, and it remains a backbone regimen in several newer combinations.\n\n| Key fact | Detail |\n|---|---|\n| Standard composition | Bendamustine 90 mg/m2 IV days 1 and 2 over 60 minutes; rituximab 375 mg/m2 cycle 1, then 500 mg/m2 cycles 2 to 6; 28-day cycles, maximum 6[1](https://www.bccancer.bc.ca/chemotherapy-protocols-site/Documents/Lymphoma-Myeloma/LYBENDR_Protocol.pdf) • [2](https://doi.org/10.1200/jco.2011.39.2688) |\n| First combination report | Rummel and colleagues, Journal of Clinical Oncology, 2005[3](https://doi.org/10.1200/jco.2005.08.100) |\n| First-line indolent NHL/MCL (StiL) | Median PFS 69.5 vs 31.2 months versus R-CHOP (HR 0.58)[4](https://doi.org/10.1016/s0140-6736%2812%2961763-2) |\n| First-line CLL (CLL10) | PFS 41.7 months, not non-inferior to FCR (55.2 months), but less myelosuppression and infection[5](https://pubmed.ncbi.nlm.nih.gov/27216274/) |\n| Relapsed CLL benchmark | Venetoclax-rituximab improved PFS over BR with HR 0.17 in the Murano trial[6](https://cdn.clinicaltrials.gov/large-docs/71/NCT02005471/Prot_002.pdf) |\n| US approval of bendamustine | CLL in March 2008; rituximab-refractory indolent B-cell NHL in October 2008[7](https://pubmed.ncbi.nlm.nih.gov/20110042/) |\n| Lifelong safety rule | Only irradiated blood products for life after bendamustine exposure[8](https://www.uhs.nhs.uk/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Bendamustine-90-Rituximab.pdf) |\n\n## How it works\n\nBendamustine's anti-neoplastic effect comes from its dual functional properties as an alkylating agent and a nitrogen mustard.[9](https://cdn.clinicaltrials.gov/large-docs/57/NCT01754857/Prot_SAP_000.pdf) A 2008 laboratory study by Lorenzo M. Leoni and colleagues reported that the drug displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents.[10](https://doi.org/10.1158/1078-0432.ccr-07-1061) [Metabolism](https://www.edgepedia.org/metabolism) involves the cytochrome P450 isoenzyme CYP1A2.[11](https://nssg.oxford-haematology.org.uk/lymphoma/documents/lymphoma-chemo-protocols/L-44-bendamustine-70-r-cll.pdf)\n\nRituximab is an anti-CD20 antibody.[12](https://ascopubs.org/doi/10.1200/JCO.2010.33.8061) The combination rests on demonstrated synergy: in vitro studies in primary CLL cells showed synergistic proapoptotic effects of bendamustine plus rituximab, which motivated the clinical pairing.[12](https://ascopubs.org/doi/10.1200/JCO.2010.33.8061)\n\n## How it is done\n\nThe standard schedule gives bendamustine 90 mg/m2 IV in 250 to 500 mL normal saline over 60 minutes on days 1 and 2, with rituximab 375 mg/m2 on day 1 or 2, repeated every 28 days for a maximum of six cycles.[1](https://www.bccancer.bc.ca/chemotherapy-protocols-site/Documents/Lymphoma-Myeloma/LYBENDR_Protocol.pdf) In CLL, rituximab is given at 375 mg/m2 on day 0 of the first course and 500 mg/m2 on day 1 of subsequent courses, for up to six courses.[2](https://doi.org/10.1200/jco.2011.39.2688) In relapsed CLL the bendamustine dose is reduced to 70 mg/m2 on days 1 and 2, the schedule used for the BR comparator arm of the Murano trial.[6](https://cdn.clinicaltrials.gov/large-docs/71/NCT02005471/Prot_002.pdf)\n\nThe first rituximab infusion starts at 50 mg/h and, after one hour, increases by 50 mg/h every 30 minutes until 400 mg/h is reached.[1](https://www.bccancer.bc.ca/chemotherapy-protocols-site/Documents/Lymphoma-Myeloma/LYBENDR_Protocol.pdf) If the cycle-1 lymphocyte count exceeds 25 x 10^9/L, the rituximab dose is split, giving 50 mg/m2 (or a 100 mg flat dose) on day 1 and the remaining 325 mg/m2 on day 2, to reduce cytokine-release risk.[11](https://nssg.oxford-haematology.org.uk/lymphoma/documents/lymphoma-chemo-protocols/L-44-bendamustine-70-r-cll.pdf) [Allopurinol](https://www.edgepedia.org/allopurinol) is not routinely prescribed with bendamustine-containing regimens because concomitant use can increase the risk of serious skin reactions.[13](https://www.cancercare.mb.ca/export/sites/default/For-Health-Professionals/.galleries/files/treatment-guidelines-rro-files/regimen-reference-orders/lymphoproliferative-disorders/LYMP-R-bendamustine.pdf) Patients treated with bendamustine carry a lifelong risk of transfusion-associated graft-versus-host disease and must receive only irradiated blood products for life.[8](https://www.uhs.nhs.uk/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Bendamustine-90-Rituximab.pdf)\n\n## Origin\n\nBendamustine was available in Europe from 1971 until 1992 under the name Cytostasan.[9](https://cdn.clinicaltrials.gov/large-docs/57/NCT01754857/Prot_SAP_000.pdf) The US FDA approved it for CLL in March 2008 and for rituximab-refractory indolent B-cell NHL in October 2008.[7](https://pubmed.ncbi.nlm.nih.gov/20110042/)\n\nThe combination was first reported by Mathias J. Rummel and colleagues in the Journal of Clinical Oncology in 2005, in a multicenter phase II study of 63 patients with mantle cell or low-grade lymphoma in first to third relapse or refractory disease; that trial gave bendamustine 90 mg/m2 as a 30-minute infusion on days 1 and 2 with rituximab 375 mg/m2 on day 1, for a maximum of four cycles every 4 weeks.[3](https://doi.org/10.1200/jco.2005.08.100) Fifty-seven of 63 patients responded (overall response rate 90%, complete remission rate 60%), with median progression-free survival of 24 months.[3](https://doi.org/10.1200/jco.2005.08.100) The German CLL Study Group then ran a trial to prospectively assess BR in relapsed or refractory CLL (78 patients), followed by a phase II trial in previously untreated CLL reported in 2012.[12](https://ascopubs.org/doi/10.1200/JCO.2010.33.8061) • [2](https://doi.org/10.1200/jco.2011.39.2688) The pivotal phase 3 studies were the German StiL NHL1 trial reported in [The Lancet](https://www.edgepedia.org/the-lancet) in 2013 by Rummel and colleagues, and the global BRIGHT study reported in Blood in 2014 by Ian W. Flinn and colleagues.[4](https://doi.org/10.1016/s0140-6736%2812%2961763-2) • [14](https://doi.org/10.1182/blood-2013-11-531327)\n\n## Variants\n\n**Rituximab maintenance.** In the StiL relapsed trial, patients who received rituximab maintenance after complete response had a significantly longer median PFS than those who did not (72.1 vs 30.4 months, \\( P = 0.01 \\)).[15](https://tcr.amegroups.org/article/view/9629/html) A dedicated analysis of maintenance rituximab after first-line BR in follicular lymphoma was reported from the BRIGHT trial by Brad S. Kahl and colleagues in 2017.[16](https://doi.org/10.1182/blood.v130.suppl_1.484.484)\n\n**Add-on strategies.** In the ECOG-ACRIN E2408 three-arm phase II trial in untreated high-risk follicular lymphoma, adding bortezomib to BR induction raised the complete response rate to 75% versus 62% for BR alone (\\( P = 0.04 \\)), but adding lenalidomide to post-induction rituximab maintenance lowered 1-year disease-free survival to 67% versus 85% (\\( P = 0.0009 \\)); the authors recommended neither addition.[17](https://aacrjournals.org/clincancerres/article/26/17/4468/82854/A-Three-Arm-Randomized-Phase-II-Study-of)\n\n**Obinutuzumab plus bendamustine.** In rituximab-refractory indolent NHL, the GADOLIN phase 3 trial by [Laurie H. Sehn](https://www.edgepedia.org/laurie-h-sehn) and colleagues compared obinutuzumab plus bendamustine with bendamustine alone; median overall survival was not reached with the combination versus 60.3 months with bendamustine (HR 0.71, 95% CI 0.51 to 0.98).[18](https://doi.org/10.1016/s1470-2045%2816%2930097-3) NICE recommends obinutuzumab with bendamustine followed by obinutuzumab maintenance for follicular lymphoma that did not respond to, or progressed during or within 6 months of, rituximab-containing treatment.[19](https://www.nice.org.uk/guidance/ta629/resources/obinutuzumab-with-bendamustine-for-treating-follicular-lymphoma-after-rituximab-pdf-82609025654725)\n\n## Applications\n\n**First-line indolent and mantle cell lymphoma.** In StiL NHL1 (81 German centers, 2003 to 2008), bendamustine 90 mg/m2 days 1 and 2 of a 4-week cycle plus rituximab 375 mg/m2 gave a median PFS of 69.5 months versus 31.2 months with R-CHOP (HR 0.58, 95% CI 0.44 to 0.74).[4](https://doi.org/10.1016/s0140-6736%2812%2961763-2) In BRIGHT, BR was noninferior to investigator-preassigned R-CHOP/R-CVP for the primary endpoint of complete response rate (31% vs 25%), with overall response rates of 97% versus 91%.[14](https://doi.org/10.1182/blood-2013-11-531327)\n\n**Relapsed indolent and mantle cell lymphoma.** Against fludarabine-rituximab, BR prolonged median PFS (34.2 vs 11.7 months, HR 0.54) and, at a median follow-up of 8 years, median overall survival (109.7 vs 49.1 months, \\( P = 0.012 \\)), with overall response rates of 82% versus 51%.[20](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2815%2900447-7/abstract) • [15](https://tcr.amegroups.org/article/view/9629/html)\n\n**CLL.** In previously untreated patients, BR produced an overall response rate of 88.0% with 23.1% complete responses; 37.5% of patients with del(17p) responded.[2](https://doi.org/10.1200/jco.2011.39.2688) In relapsed or refractory CLL, the response rate was 59.0% with 9.0% complete responses and median event-free survival of 14.7 months.[12](https://ascopubs.org/doi/10.1200/JCO.2010.33.8061)\n\n## Limitations and alternatives\n\n**Versus R-CHOP.** BR was better tolerated than R-CHOP in StiL, with no alopecia (versus 100% of R-CHOP patients receiving at least 3 cycles), hematologic toxicity in 30% versus 68%, and erythematous skin reactions more common with BR (16% vs 9%).[4](https://doi.org/10.1016/s0140-6736%2812%2961763-2) In BRIGHT, vomiting and drug-hypersensitivity reactions were significantly higher with BR, while peripheral neuropathy/paresthesia and alopecia were higher with R-CHOP/R-CVP.[14](https://doi.org/10.1182/blood-2013-11-531327)\n\n**Versus FCR in CLL.** In CLL10, median PFS was 41.7 months with BR versus 55.2 months with FCR (HR 1.643, 90.4% CI 1.308 to 2.064), so non-inferiority was not shown; severe neutropenia (59% vs 84%) and infections (25% vs 39%) were less frequent with BR, and the authors concluded FCR remains standard front-line therapy in fit patients while BR is associated with less toxic effects.[5](https://pubmed.ncbi.nlm.nih.gov/27216274/)\n\n**Versus targeted therapy.** In a matched-adjusted indirect comparison restricted to CLL patients with intact 17p who had received chemoimmunotherapy first line, there was no overall survival difference between ibrutinib (63% alive at 36 months) and BR (74.4% alive at 36 months).[21](https://haematologica.org/article/view/8525) In relapsed CLL, however, the Murano trial showed a highly significant PFS advantage for venetoclax-rituximab over BR, with a hazard ratio of 0.17 (95% CI 0.11 to 0.25; \\( p < 0.0001 \\)).[6](https://cdn.clinicaltrials.gov/large-docs/71/NCT02005471/Prot_002.pdf) • [21](https://haematologica.org/article/view/8525)\n\n**Failure modes and safety.** BR has shown only limited efficacy in patients refractory to fludarabine or with TP53 deletions or mutations.[11](https://nssg.oxford-haematology.org.uk/lymphoma/documents/lymphoma-chemo-protocols/L-44-bendamustine-70-r-cll.pdf) Response rates are lower in rituximab-pretreated (57%) than rituximab-naive (75%) patients.[15](https://tcr.amegroups.org/article/view/9629/html) Myelosuppression is the major toxicity: grade 3 to 4 leukocytopenia reached 16% in the 2005 phase II study, grade 3/4 neutropenia 23.1% in relapsed CLL and 19.7% in previously untreated CLL, with severe infections in 12.8% of relapsed patients.[3](https://doi.org/10.1200/jco.2005.08.100) • [12](https://ascopubs.org/doi/10.1200/JCO.2010.33.8061) • [2](https://doi.org/10.1200/jco.2011.39.2688) Infusion-related adverse reactions of all kinds occur in about 77% of rituximab-treated patients, including cytokine release syndrome in about 10%.[8](https://www.uhs.nhs.uk/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Bendamustine-90-Rituximab.pdf) • [24](https://www.ema.europa.eu/en/documents/product-information/ruxience-epar-product-information_en.pdf) Fatal cytokine release syndrome with rituximab usually occurs within 1 to 2 hours of the first infusion, and tumor lysis syndrome with bendamustine usually has onset during the first cycle.[1](https://www.bccancer.bc.ca/chemotherapy-protocols-site/Documents/Lymphoma-Myeloma/LYBENDR_Protocol.pdf) Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported when bendamustine and allopurinol are given simultaneously.[11](https://nssg.oxford-haematology.org.uk/lymphoma/documents/lymphoma-chemo-protocols/L-44-bendamustine-70-r-cll.pdf) BR also causes prolonged lymphopenia requiring PJP and herpes prophylaxis, and specialists advise avoiding BR immediately before CAR-T collection.[22](https://onco.cc/regimens/br/)\n\n**Open questions.** BR's role as a backbone continues to be explored; the B-R-ENDA authors suggested polatuzumab vedotin combined with BR might be an interesting option to study for elderly and frail DLBCL patients even up front.[23](https://pmc.ncbi.nlm.nih.gov/articles/PMC9722574/) Published comparisons do not settle BR's current positioning against BTK inhibitors as first-line choices, bispecific antibodies, or CAR-T.\n\n## References\n\n1. [BC Cancer Protocol Summary LYBENDR (bendamustine and riTUXimab for non-Hodgkin lymphoma)](https://www.bccancer.bc.ca/chemotherapy-protocols-site/Documents/Lymphoma-Myeloma/LYBENDR_Protocol.pdf)\n2. [Kirsten Fischer and colleagues (2012). Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group. Journal of Clinical Oncology.](https://doi.org/10.1200/jco.2011.39.2688)\n3. [Mathias J. Rummel and colleagues (2005). Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma. Journal of Clinical Oncology.](https://doi.org/10.1200/jco.2005.08.100)\n4. [Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial (The Lancet, 2013)](https://doi.org/10.1016/s0140-6736%2812%2961763-2)\n5. [CLL10: first-line BR versus FCR in advanced CLL, international open-label randomised phase 3 non-inferiority trial (Lancet Oncology 2016)](https://pubmed.ncbi.nlm.nih.gov/27216274/)\n6. [Murano trial protocol (NCT02005471), version 9, 30 March 2018: venetoclax-rituximab versus BR in relapsed/refractory CLL](https://cdn.clinicaltrials.gov/large-docs/71/NCT02005471/Prot_002.pdf)\n7. [Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma (review, 2010)](https://pubmed.ncbi.nlm.nih.gov/20110042/)\n8. [UHS (Southampton) Chemotherapy SOP: Bendamustine (90)-Rituximab for CLL](https://www.uhs.nhs.uk/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Bendamustine-90-Rituximab.pdf)\n9. [Celgene protocol CDC-501-MEL-001: BR induction followed by maintenance rituximab and lenalidomide in previously untreated CLL/SLL](https://cdn.clinicaltrials.gov/large-docs/57/NCT01754857/Prot_SAP_000.pdf)\n10. [Lorenzo M. Leoni and colleagues (2008). Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents. Clinical Cancer Research.](https://doi.org/10.1158/1078-0432.ccr-07-1061)\n11. [NSSG Chemotherapy Protocol: Bendamustine + Rituximab (BR) for CLL](https://nssg.oxford-haematology.org.uk/lymphoma/documents/lymphoma-chemo-protocols/L-44-bendamustine-70-r-cll.pdf)\n12. [Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German CLL Study Group (Fischer et al., JCO 2011)](https://ascopubs.org/doi/10.1200/JCO.2010.33.8061)\n13. [CancerCare Manitoba Regimen Reference Order: LYMP – R-bendamustine (updated June 26, 2024)](https://www.cancercare.mb.ca/export/sites/default/For-Health-Professionals/.galleries/files/treatment-guidelines-rro-files/regimen-reference-orders/lymphoproliferative-disorders/LYMP-R-bendamustine.pdf)\n14. [Ian W. Flinn and colleagues (2014). Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood.](https://doi.org/10.1182/blood-2013-11-531327)\n15. [Bendamustine and rituximab for the treatment of relapsed indolent and mantle cell lymphoma: when timing of a study matters (Falchi, Translational Cancer Research)](https://tcr.amegroups.org/article/view/9629/html)\n16. [Brad S. Kahl and colleagues (2017). Assessment of Maintenance Rituximab after First-Line Bendamustine-Rituximab in Patients with Follicular Lymphoma: An Analysis from the BRIGHT Trial. Blood.](https://doi.org/10.1182/blood.v130.suppl_1.484.484)\n17. [A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408](https://aacrjournals.org/clincancerres/article/26/17/4468/82854/A-Three-Arm-Randomized-Phase-II-Study-of)\n18. [Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial (The Lancet Oncology, 2016)](https://doi.org/10.1016/s1470-2045%2816%2930097-3)\n19. [Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (NICE TA629)](https://www.nice.org.uk/guidance/ta629/resources/obinutuzumab-with-bendamustine-for-treating-follicular-lymphoma-after-rituximab-pdf-82609025654725)\n20. [abstract (thelancet.com)](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2815%2900447-7/abstract)\n21. [Efficacy of BR as first salvage treatment in CLL and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study (Haematologica)](https://haematologica.org/article/view/8525)\n22. [OnCo regimen reference: Bendamustine + rituximab (BR)](https://onco.cc/regimens/br/)\n23. [First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial (DSHNHL)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9722574/)\n24. [Ruxience Epar Product Information En.pdf, ema.europa.eu](https://www.ema.europa.eu/en/documents/product-information/ruxience-epar-product-information_en.pdf)\n\n---\n*Topic: Encyclopedia › Life and health › Human health and medicine › Medicines and therapeutics › Cancer chemotherapy and regimens › Immunotherapy and immunochemotherapy*\n\n*Initially written Sep 29, 2026 · Reviewed: Sep 30, 2026 · Edited: Oct 15, 2026 · Last review: Sep 30, 2026*\n\n*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*\n\nLicense: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license\n", "same_as": [], "url": "https://www.edgepedia.org/bendamustine-and-rituximab-regimen", "markdown_url": "https://www.edgepedia.org/bendamustine-and-rituximab-regimen.md", "license": { "name": "Edgepedia Community License 1.0", "url": "https://www.edgepedia.org/edgepedia/license", "summary": "Free with credit, commercial use included. AI training is open to everyone. For other uses, organizations over USD 100M in revenue or 100M monthly users license separately.", "spdx": "LicenseRef-Edgepedia-Community-1.0" }, "credit": "\"Bendamustine and rituximab regimen\", Edgepedia (EdgeChat), https://www.edgepedia.org/bendamustine-and-rituximab-regimen. Edgepedia Community License 1.0.", "credit_md": "\"[Bendamustine and rituximab regimen](https://www.edgepedia.org/bendamustine-and-rituximab-regimen)\", Edgepedia (EdgeChat), [https://www.edgepedia.org/bendamustine-and-rituximab-regimen](https://www.edgepedia.org/bendamustine-and-rituximab-regimen). [Edgepedia Community License 1.0](https://www.edgepedia.org/edgepedia/license).", "credit_html": "\"Bendamustine and rituximab regimen\", Edgepedia (EdgeChat), https://www.edgepedia.org/bendamustine-and-rituximab-regimen. Edgepedia Community License 1.0.", "speakable": "The bendamustine and rituximab regimen is a chemoimmunotherapy combination pairing the alkylating drug bendamustine with the antibody rituximab, given in up to six 28-day cycles for B-cell malignancies including indolent lymphoma and CLL." }